Designing CAF-adjuvanted dry powder vaccines: spray drying preserves the adjuvant activity of CAF01

Research output: Contribution to journalJournal articlepeer-review

Standard

Designing CAF-adjuvanted dry powder vaccines : spray drying preserves the adjuvant activity of CAF01. / Ingvarsson, Pall Thor; Schmidt, Signe Tandrup; Christensen, Dennis; Larsen, Niels Bent; Hinrichs, Wouter Leonardus Joseph; Andersen, Peter; Rantanen, Jukka; Nielsen, Hanne Mørck; Yang, Mingshi; Foged, Camilla.

In: Journal of Controlled Release, Vol. 167, No. 3, 08.02.2013, p. 256-264.

Research output: Contribution to journalJournal articlepeer-review

Harvard

Ingvarsson, PT, Schmidt, ST, Christensen, D, Larsen, NB, Hinrichs, WLJ, Andersen, P, Rantanen, J, Nielsen, HM, Yang, M & Foged, C 2013, 'Designing CAF-adjuvanted dry powder vaccines: spray drying preserves the adjuvant activity of CAF01', Journal of Controlled Release, vol. 167, no. 3, pp. 256-264. https://doi.org/10.1016/j.jconrel.2013.01.031

APA

Ingvarsson, P. T., Schmidt, S. T., Christensen, D., Larsen, N. B., Hinrichs, W. L. J., Andersen, P., Rantanen, J., Nielsen, H. M., Yang, M., & Foged, C. (2013). Designing CAF-adjuvanted dry powder vaccines: spray drying preserves the adjuvant activity of CAF01. Journal of Controlled Release, 167(3), 256-264. https://doi.org/10.1016/j.jconrel.2013.01.031

Vancouver

Ingvarsson PT, Schmidt ST, Christensen D, Larsen NB, Hinrichs WLJ, Andersen P et al. Designing CAF-adjuvanted dry powder vaccines: spray drying preserves the adjuvant activity of CAF01. Journal of Controlled Release. 2013 Feb 8;167(3):256-264. https://doi.org/10.1016/j.jconrel.2013.01.031

Author

Ingvarsson, Pall Thor ; Schmidt, Signe Tandrup ; Christensen, Dennis ; Larsen, Niels Bent ; Hinrichs, Wouter Leonardus Joseph ; Andersen, Peter ; Rantanen, Jukka ; Nielsen, Hanne Mørck ; Yang, Mingshi ; Foged, Camilla. / Designing CAF-adjuvanted dry powder vaccines : spray drying preserves the adjuvant activity of CAF01. In: Journal of Controlled Release. 2013 ; Vol. 167, No. 3. pp. 256-264.

Bibtex

@article{40e0c08a5440496cb14cb3a7a1237dec,
title = "Designing CAF-adjuvanted dry powder vaccines: spray drying preserves the adjuvant activity of CAF01",
abstract = "Dry powder vaccine formulations are highly attractive due to improved storage stability and the possibility for particle engineering, as compared to liquid formulations. However, a prerequisite for formulating vaccines into dry formulations is that their physicochemical and adjuvant properties remain unchanged upon rehydration. Thus, we have identified and optimized the parameters of importance for the design of a spray dried powder formulation of the cationic liposomal adjuvant formulation 01 (CAF01) composed of dimethyldioctadecylammonium (DDA) bromide and trehalose 6,6'-dibehenate (TDB) via spray drying. The optimal excipient to stabilize CAF01 during spray drying and for the design of nanocomposite microparticles was identified among mannitol, lactose and trehalose. Trehalose and lactose were promising stabilizers with respect to preserving liposome size, as compared to mannitol. Trehalose and lactose were in the glassy state upon co-spray drying with the liposomes, whereas mannitol appeared crystalline, suggesting that the ability of the stabilizer to form a glassy matrix around the liposomes is one of the prerequisites for stabilization. Systematic studies on the effect of process parameters suggested that a fast drying rate is essential to avoid phase separation and lipid accumulation at the surface of the microparticles during spray drying. Finally, immunization studies in mice with CAF01 in combination with the tuberculosis antigen Ag85B-ESAT6-Rv2660c (H56) demonstrated that spray drying of CAF01 with trehalose under optimal processing conditions resulted in the preservation of the adjuvant activity in vivo. These data demonstrate the importance of liposome stabilization via optimization of formulation and processing conditions in the engineering of dry powder liposome formulations.",
author = "Ingvarsson, {Pall Thor} and Schmidt, {Signe Tandrup} and Dennis Christensen and Larsen, {Niels Bent} and Hinrichs, {Wouter Leonardus Joseph} and Peter Andersen and Jukka Rantanen and Nielsen, {Hanne M{\o}rck} and Mingshi Yang and Camilla Foged",
note = "Copyright {\textcopyright} 2013. Published by Elsevier B.V.",
year = "2013",
month = feb,
day = "8",
doi = "10.1016/j.jconrel.2013.01.031",
language = "English",
volume = "167",
pages = "256--264",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "3",

}

RIS

TY - JOUR

T1 - Designing CAF-adjuvanted dry powder vaccines

T2 - spray drying preserves the adjuvant activity of CAF01

AU - Ingvarsson, Pall Thor

AU - Schmidt, Signe Tandrup

AU - Christensen, Dennis

AU - Larsen, Niels Bent

AU - Hinrichs, Wouter Leonardus Joseph

AU - Andersen, Peter

AU - Rantanen, Jukka

AU - Nielsen, Hanne Mørck

AU - Yang, Mingshi

AU - Foged, Camilla

N1 - Copyright © 2013. Published by Elsevier B.V.

PY - 2013/2/8

Y1 - 2013/2/8

N2 - Dry powder vaccine formulations are highly attractive due to improved storage stability and the possibility for particle engineering, as compared to liquid formulations. However, a prerequisite for formulating vaccines into dry formulations is that their physicochemical and adjuvant properties remain unchanged upon rehydration. Thus, we have identified and optimized the parameters of importance for the design of a spray dried powder formulation of the cationic liposomal adjuvant formulation 01 (CAF01) composed of dimethyldioctadecylammonium (DDA) bromide and trehalose 6,6'-dibehenate (TDB) via spray drying. The optimal excipient to stabilize CAF01 during spray drying and for the design of nanocomposite microparticles was identified among mannitol, lactose and trehalose. Trehalose and lactose were promising stabilizers with respect to preserving liposome size, as compared to mannitol. Trehalose and lactose were in the glassy state upon co-spray drying with the liposomes, whereas mannitol appeared crystalline, suggesting that the ability of the stabilizer to form a glassy matrix around the liposomes is one of the prerequisites for stabilization. Systematic studies on the effect of process parameters suggested that a fast drying rate is essential to avoid phase separation and lipid accumulation at the surface of the microparticles during spray drying. Finally, immunization studies in mice with CAF01 in combination with the tuberculosis antigen Ag85B-ESAT6-Rv2660c (H56) demonstrated that spray drying of CAF01 with trehalose under optimal processing conditions resulted in the preservation of the adjuvant activity in vivo. These data demonstrate the importance of liposome stabilization via optimization of formulation and processing conditions in the engineering of dry powder liposome formulations.

AB - Dry powder vaccine formulations are highly attractive due to improved storage stability and the possibility for particle engineering, as compared to liquid formulations. However, a prerequisite for formulating vaccines into dry formulations is that their physicochemical and adjuvant properties remain unchanged upon rehydration. Thus, we have identified and optimized the parameters of importance for the design of a spray dried powder formulation of the cationic liposomal adjuvant formulation 01 (CAF01) composed of dimethyldioctadecylammonium (DDA) bromide and trehalose 6,6'-dibehenate (TDB) via spray drying. The optimal excipient to stabilize CAF01 during spray drying and for the design of nanocomposite microparticles was identified among mannitol, lactose and trehalose. Trehalose and lactose were promising stabilizers with respect to preserving liposome size, as compared to mannitol. Trehalose and lactose were in the glassy state upon co-spray drying with the liposomes, whereas mannitol appeared crystalline, suggesting that the ability of the stabilizer to form a glassy matrix around the liposomes is one of the prerequisites for stabilization. Systematic studies on the effect of process parameters suggested that a fast drying rate is essential to avoid phase separation and lipid accumulation at the surface of the microparticles during spray drying. Finally, immunization studies in mice with CAF01 in combination with the tuberculosis antigen Ag85B-ESAT6-Rv2660c (H56) demonstrated that spray drying of CAF01 with trehalose under optimal processing conditions resulted in the preservation of the adjuvant activity in vivo. These data demonstrate the importance of liposome stabilization via optimization of formulation and processing conditions in the engineering of dry powder liposome formulations.

U2 - 10.1016/j.jconrel.2013.01.031

DO - 10.1016/j.jconrel.2013.01.031

M3 - Journal article

C2 - 23415813

VL - 167

SP - 256

EP - 264

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 3

ER -

ID: 44836512